Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epimedin A
- Development stage
- Preclinical
- Lead developer
- Noorda College of Osteopathic Medicine
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Epimedin A is a flavonoid glycoside isolated from the *Epimedium* genus (commonly known as Horny Goat Weed). It is currently under preclinical investigation for its potential therapeutic application in glioblastoma. Research indicates that Epimedin A inhibits the proliferation, migration, and invasion of glioblastoma cells, such as the U87 line, in a dose-dependent manner. Its mechanism of action involves the induction of apoptosis through the activation of Caspase-3 and the subsequent cleavage of PARP. Furthermore, Epimedin A regulates the expression of several pro- and anti-apoptotic factors, including Bcl-x, HIF-1alpha, Bad, Bax, Cytochrome C, and SMAC/Diablo, and has been shown to reduce the formation of reactive oxygen species (ROS) in cancer cells.
- Other names
- epimedoside A
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)BAD (Bcl-2-associated agonist of cell death)BCL2L1 (B-cell lymphoma-extra large protein)CYCS (Cytochrome c)BAX (Apoptosis regulator BAX)HIF1A (Hypoxia-inducible factor 1-alpha)SMACCASP3 (Caspase-3)
Beyond the preview
Go deeper on epimedin A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epimedin A.